Trimethylamine-N-oxide is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation.
Luciani M, Müller D, Vanetta C, Diteepeng T, von Eckardstein A, Aeschbacher S, Rodondi N, Moschovitis G, Reichlin T, Sinnecker T, Wuerfel J, Bonati LH, Saeedi Saravi SS, Chocano-Bedoya P, Coslovsky M, Camici GG, Lüscher TF, Kuehne M, Osswald S, Conen D, Beer JH; SWISS-AF Investigators.
Luciani M, et al. Among authors: saeedi saravi ss.
Heart. 2023 Feb 14;109(5):396-404. doi: 10.1136/heartjnl-2022-321300.
Heart. 2023.
PMID: 36593094
Clinical Trial.